Montelukast effects on inflammation in allergic rhinitis: A double blind placebo controlled pilot study

European Annals of Allergy and Clinical Immunology

Volumn 44, Issue 2, 2012, Pages 48-54

  Braido, F ^a   Riccio, A M ^a   Rogkakou, A ^a   Massacane, P ^a   Guerra, L ^a   Fumagalli, F ^a   Stagi, E ^a   Balestracci, S ^a   Porcu, A ^a   Canonica, G W ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergic rhinitis; Eosinophils; Montelukast

Indexed keywords

MONTELUKAST; PLACEBO;

ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; CELL COUNT; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EOSINOPHIL COUNT; EVENING DOSAGE; FEMALE; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LYMPHOCYTE COUNT; MACROPHAGE; MALE; NASAL CHALLENGE; NEUTROPHIL COUNT; PHENOTYPE; PILOT STUDY; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME;

ACETATES; ADULT; CELL COUNT; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; HUMANS; HYPERSENSITIVITY; INFLAMMATION; LEUKOTRIENE ANTAGONISTS; LYMPHOCYTES; MACROPHAGES; MALE; NEUTROPHILS; PILOT PROJECTS; QUINOLINES; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84860995531     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Aït-Khaled N, Pearce N, Anderson HR, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009: 64:123-48.
2. Howarth PH. The cellular basis for allergic rhinitis. Allergy 1995; 50 (23 Suppl): 6-10.
3. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16: 289-97.
4. Naclerio RM, Baroody FM, Togias AG. The role of leukotrienes in allergic rhinitis: a review. Am Rev Respir Dis. 1991; 143 (5 Pt 2): S91-5.
5. Israel E. Leukotrienes and rhinitis. Clin Exp Allergy 2001; vol 1, n 2:125-160
6. Borish L. The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. Ann Allergy Asthma Immunol 2002; 88: 16-2212.
7. Miadonna A, Tedeschi A, Leggieri E, et al. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987; 136: 357-62.
8. Volovitz B, Tabachnik E, Nussinovitch M, et al. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. J Allergy Clin Immunol 1999; 104: 1162-7.
9. Philip G, Malmstrom K, Hampel FC, et al. Montelukast Spring Rhinitis Study Group. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32: 1020-8.
10. Meltzer EO. Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. Ann Allergy Asthma Immunol 2002; 88: 23-9.
11. Wilson AM, White PS, Gardiner Q. Effects of leukotriene receptor antagonist therapy in patients with chronic rhinosinusitis in a real life rhinology clinic setting. Rhinology 2001; 39: 142-6.
12. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy. 2001; 31: 616-24.
13. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008; 63: 8-160.
14. Melillo G, Bonini S, Cocco G, et al. Standardisation of nasal provocation tests. Allergy 1997; 52: 26-33.
15. Andri L, Senna GE, Betelli C, Andri G, Falagiani P. Specific nasal provocation test with allergens in powder form proves a reliable and reproducible technique. Allergy 1992; 47: 243.
16. McCullagh P, Nelder JA. Generalized linear models. Edizione: 2, illustrata Pubblicato da CRC Press, 1989.
17. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis, July 2004, Hardcover.
18. Anderson R, Theron AJ, Gravett CM, Steel HC, Tintinger GR, Feldman C. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br J Pharmacol. 2009; 156: 105-15.
19. Gravett CM, Theron AJ, Steel HC, et al. Interactive inhibitory effects of formoterol and montelukast on activated human. Eur Respir J 2010; 36: 1417-24.
20. Julius P, Grosse-Thie C, Kuepper M, Bratke K, Virchow JC. sCD14 in bronchoalveolar lavage 18, 42 and 162 hours after segmental allergen provocation. Scand J Immunol 2010; 71: 304-11.
21. Ramires R, Caiaffa MF, Tursi A, Haeggström JZ, Macchia L. Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem Biophys Res Commun 2004; 324: 815-21.
22. Woszczek G, Chen LY, Alsaaty S, Nagineni S, Shelhamer JH. Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists. J Immunol 2010; 184: 2219-25.
23. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007; 119: 1055-62.
24. Ohnishi H, Miyahara N, Gelfand EW. The role of leukotriene B(4) in allergic diseases. Allergol Int 2008; 57: 291-8.
25. Ichiyama T, Hasegawa S, Umeda M, Terai K, Matsubara T, Furukawa S. Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells. Clin Exp Allergy. 2003; 33: 802-7.
26. Tomari S, Matsuse H, Machida I et al. Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, attenuates allergen-specific tumour necrosis factor alpha production and nuclear factor kappa B nuclear translocation in peripheral blood monocytes from atopic asthmatics. Clin Exp Allergy 2003; 33: 795-801.
27. Ishinaga H, Takeuchi K, Kishioka C, Suzuki S, Basbaum C, Majima Y. Pranlukast inhibits NF-kappaB activation and MUC2 gene expression in cultured human epithelial cells. Pharmacology 2005; 73: 89-96.
28. Maeba S, Ichiyama T, Ueno Y, Makata H, Matsubara T, Furukawa S. Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Ann Allergy Asthma Immunol 2005; 94: 670-4.